<?xml version="1.0" encoding="UTF-8"?>
<Pathway xmlns="http://pathvisio.org/GPML/2013a" Name="Cancer immunotherapy by PD-1 blockade" Version="20190430" Organism="Homo sapiens">
  <Comment Source="WikiPathways-description">Immune checkpoints are hardwired into the immune system and are crucial for maintaining self-tolerance. Tumors can use these checkpoints to protect themselves from immune system attacks. 
One such immune checkpoint is PD-1 (programmed cell death 1 protein), which binds to its ligand PD-L1 and inhibits immune cell activity, including T cell activity. By upregulating PD-L1, cancer cells can inhibit T cells that might otherwise attack.  One strategy for cancer immunotherapy is to block this kind of negative feedback, thereby increasing anti-cancer T-cell activity. For the PD-1 checkpoint, cancer immunotherapeutics block either the PD-1 receptor, or the PD-L1 ligand.
The [https://www.nobelprize.org/prizes/medicine/2018/summary/ 2018 Nobel prize in Physiology or Medicine] was awarded to jointly to James Allison and Tasuku Honjo for their discovery of cancer therapy by inhibition of negative immune regulation.

Based on and figure 4B in the review by [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856023/ Pardoll] and figure 1 in the review by [https://www.ncbi.nlm.nih.gov/pubmed/28990585 Sharpe and Pauken].
</Comment>
  <BiopaxRef>c58</BiopaxRef>
  <BiopaxRef>f89</BiopaxRef>
  <BiopaxRef>bda</BiopaxRef>
  <Graphics BoardWidth="883.0" BoardHeight="880.0"/>
  <DataNode TextLabel="Tumor-associated&#10;antigen" GraphId="a8e9d" Type="GeneProduct" GroupRef="fcdac">
        </DataNode>
  <DataNode TextLabel="Pembrolizumab" GraphId="ac967" Type="Metabolite" GroupRef="b5431">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="CD8A" GraphId="ad5ee" Type="GeneProduct" GroupRef="d89f0">
        </DataNode>
  <DataNode TextLabel="CD274" GraphId="ae75d" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="IFNG" GraphId="bbd24" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="PDCD1LG2" GraphId="c29ad" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="Ras signaling" GraphId="ca322" Type="Pathway">
    <Graphics ShapeType="None" Color="14961e"/>
    </DataNode>
  <DataNode TextLabel="Nivolumab" GraphId="cc867" Type="Metabolite" GroupRef="b5431">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="MHC I" GraphId="cf68e" Type="Protein" GroupRef="fcdac">
        </DataNode>
  <DataNode TextLabel="STAT3" GraphId="d1337" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="Pidilizumab" GraphId="d9d18" Type="Metabolite" GroupRef="b5431">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="TRA" GraphId="dedef" Type="GeneProduct" GroupRef="e28a1">
        </DataNode>
  <DataNode TextLabel="JUN" GraphId="e2c2e" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="Durvalumab" GraphId="e67ee" Type="Metabolite" GroupRef="b6590">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="BATF" GraphId="e8b31" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="Avelumab" GraphId="e9da1" Type="Metabolite" GroupRef="b6590">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="Atezolizumab" GraphId="e9dc5" Type="Metabolite" GroupRef="b6590">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="CD3D" GraphId="ee1ad" Type="GeneProduct" GroupRef="e28a1">
        </DataNode>
  <DataNode TextLabel="ZAP70" GraphId="ef0fd" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="LCK" GraphId="f1abb" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="MDX-1105" GraphId="f897c" Type="Metabolite" GroupRef="b6590">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="NFATC1" GraphId="f9482" Type="GeneProduct" GroupRef="ceb71">
        </DataNode>
  <DataNode TextLabel="PDCD1" GraphId="fb005" Type="GeneProduct" GroupRef="d0469">
        </DataNode>
  <DataNode TextLabel="AMP-224" GraphId="fb550" Type="Metabolite" GroupRef="b5431">
    <Comment>https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-pd-1-fusion-protein-amp-224</Comment>
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="PTPN11" GraphId="fb739" Type="GeneProduct" GroupRef="d0469">
        </DataNode>
  <DataNode TextLabel="Tislelizumab" GraphId="fdb08" Type="Metabolite" GroupRef="b5431">
    <Graphics Color="0000ff"/>
    </DataNode>
  <DataNode TextLabel="TRB" GraphId="c44ef" Type="GeneProduct" GroupRef="e28a1">
        </DataNode>
  <DataNode TextLabel="MHC II" GraphId="eba63" Type="Protein" GroupRef="fcdac">
        </DataNode>
  <DataNode TextLabel="BATF" GraphId="ad8ad" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="CD3E" GraphId="de57b" Type="GeneProduct" GroupRef="e28a1">
        </DataNode>
  <DataNode TextLabel="CD3G" GraphId="d8903" Type="GeneProduct" GroupRef="e28a1">
        </DataNode>
  <DataNode TextLabel="NFKB1" GraphId="ce83f" Type="GeneProduct" GroupRef="ceb71">
        </DataNode>
  <DataNode TextLabel="PI3K signaling" GraphId="deab0" Type="Pathway">
    <Graphics ShapeType="None" Color="14961e"/>
    </DataNode>
  <DataNode TextLabel="CD8B" GraphId="c5d3d" Type="GeneProduct" GroupRef="d89f0">
        </DataNode>
  <DataNode TextLabel="NFATC2" GraphId="c5fef" Type="GeneProduct" GroupRef="ceb71">
        </DataNode>
  <DataNode TextLabel="NFATC3" GraphId="d3001" Type="GeneProduct" GroupRef="ceb71">
        </DataNode>
  <DataNode TextLabel="NFATC4" GraphId="dd28d" Type="GeneProduct" GroupRef="ceb71">
        </DataNode>
  <DataNode TextLabel="NFAT5" GraphId="b49a8" Type="GeneProduct" GroupRef="ceb71">
        </DataNode>
  <State GraphRef="fb005" TextLabel="P" GraphId="ac39e">
    <Comment>parentid=Q15116; parentsymbol=PDCD1; site=CVPEQTEyATIVFPS; position=tyr248; sitegrpid=50293001; ptm=p; direction=u
</Comment>
    <Graphics ShapeType="Oval"/>
    </State>
  <State GraphRef="ef0fd" TextLabel="P" GraphId="d4b68">
    <Comment>parentid=P43403; parentsymbol=ZAP70; site=tsVyEsPysDPEELk; position=tyr319; sitegrpid=447587; ptm=p; direction=u
</Comment>
    <Graphics ShapeType="Oval"/>
    </State>
  <State GraphRef="ef0fd" TextLabel="P" GraphId="e9c50">
    <Comment>parentid=P43403; parentsymbol=ZAP70; site=VLLVNRHyAkISDFG; position=tyr474; sitegrpid=455368; ptm=p; direction=u
</Comment>
    <Graphics ShapeType="Oval"/>
    </State>
  <State GraphRef="fb005" TextLabel="P" GraphId="f35c8">
    <Comment>parentid=Q15116; parentsymbol=PDCD1; site=VPVFSVDyGELDFQW; position=tyr223; sitegrpid=450293000; ptm=p; direction=u
</Comment>
    <Graphics ShapeType="Oval"/>
    </State>
  <Interaction GraphId="id12ce76b1">
    <Graphics ConnectorType="Elbow">
      <Point GraphRef="fb739"/>
      <Point GraphRef="ef0fd" ArrowHead="mim-inhibition"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id165d1846">
    <Graphics>
      <Point GraphRef="ca322"/>
      <Point GraphRef="d0d3d" ArrowHead="Arrow"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id1e85e2e8">
    <Graphics ConnectorType="Elbow">
      <Point GraphRef="cf68e"/>
      <Point GraphRef="dee64" ArrowHead="mim-binding"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id233b9269">
    <Graphics>
      <Point GraphRef="ae75d"/>
      <Point GraphRef="fb005" ArrowHead="mim-binding"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id3dfabd77">
    <Graphics>
      <Point GraphRef="fb739"/>
      <Point GraphRef="e8b31" ArrowHead="Arrow"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id4edd403d">
    <Graphics>
      <Point GraphRef="d0d3d"/>
      <Point GraphRef="d7a36" ArrowHead="Arrow"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id52d664a5">
    <Graphics>
      <Point GraphRef="ef0fd"/>
      <Point GraphRef="deab0" ArrowHead="Arrow"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id546b3fb4">
    <Graphics>
      <Point GraphRef="d76c9"/>
      <Point GraphRef="fb005" ArrowHead="mim-inhibition"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id7ed4b1c1">
    <Graphics>
      <Point GraphRef="ef0fd"/>
      <Point GraphRef="ca322" ArrowHead="Arrow"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="id9baa23b1">
    <Graphics ConnectorType="Elbow">
      <Point GraphRef="fb739"/>
      <Point GraphRef="bbd24" ArrowHead="Arrow"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="ida0613b62">
    <BiopaxRef>abc</BiopaxRef>
    <BiopaxRef>e61</BiopaxRef>
    <BiopaxRef>ca1</BiopaxRef>
    <Graphics>
      <Point GraphRef="cf802"/>
      <Point GraphRef="ae75d" ArrowHead="mim-inhibition"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="idd2218871">
    <Graphics>
      <Point GraphRef="a8e9d"/>
      <Point GraphRef="ac0b9" ArrowHead="mim-binding"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="iddb7061af">
    <Graphics>
      <Point GraphRef="d1337"/>
      <Point GraphRef="ae75d" ArrowHead="Arrow"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="iddd6753bb">
    <Graphics ConnectorType="Elbow">
      <Point GraphRef="bbd24"/>
      <Point GraphRef="d1337" ArrowHead="Arrow"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="ide1f72d6e">
    <Graphics>
      <Point GraphRef="c29ad"/>
      <Point GraphRef="fb005" ArrowHead="mim-binding"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="idfba37d0">
    <Graphics ConnectorType="Elbow">
      <Point GraphRef="fb739"/>
      <Point GraphRef="deab0" ArrowHead="mim-inhibition"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="idfbed420c">
    <Graphics>
      <Point GraphRef="e8b31"/>
      <Point GraphRef="ad8ad" ArrowHead="Arrow"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="d1188">
    <Graphics ConnectorType="Elbow">
      <Point GraphRef="fb739"/>
      <Point GraphRef="ca322" ArrowHead="mim-inhibition"/>
    </Graphics>
    </Interaction>
  <Interaction GraphId="dcb2a">
    <Graphics>
      <Point GraphRef="deab0"/>
      <Point GraphRef="d0d3d" ArrowHead="Arrow"/>
    </Graphics>
    </Interaction>
  <Label TextLabel="T cell activation&#10;Growth&#10;Proliferation&#10;Survival" GraphId="d7a36">
    <Graphics FillColor="ffffff"/>
  </Label>
  <Label TextLabel="T-cell induced&#10;PDL1 upregulation" GraphId="df06b">
    <Graphics FillColor="ffffff"/>
  </Label>
  <Shape TextLabel="T cell" GraphId="de6ca">
    <Graphics Align="Left" ShapeType="RoundedRectangle" Color="c0c0c0"/>
  </Shape>
  <Shape TextLabel="Tumor cell" GraphId="f5559">
    <Graphics Align="Left" ShapeType="RoundedRectangle" Color="c0c0c0"/>
  </Shape>
  <Shape TextLabel="Nucleus" GraphId="e6439">
    <Graphics ShapeType="RoundedRectangle" Color="c0c0c0"/>
  </Shape>
  <Group GroupId="e28a1" GraphId="ac0b9" Style="Complex"/>
  <Group GroupId="fcdac" GraphId="cf5ce" Style="Complex"/>
  <Group GroupId="b6590" GraphId="cf802" Style="Group"/>
  <Group GroupId="ceb71" GraphId="d0d3d" Style="Group"/>
  <Group GroupId="b5431" GraphId="d76c9" Style="Group"/>
  <Group GroupId="d89f0" GraphId="dee64" Style="Group"/>
  <Group GroupId="d0469" GraphId="e03e1" Style="Group"/>
  <InfoBox/>
  <Biopax>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="c58">
      <bp:ID >30511409</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Immune checkpoint blockade opens a new way to cancer immunotherapy.</bp:TITLE>
      <bp:SOURCE >J Cell Physiol</bp:SOURCE>
      <bp:YEAR >2019</bp:YEAR>
      <bp:AUTHORS >Sadreddini S</bp:AUTHORS>
      <bp:AUTHORS >Baradaran B</bp:AUTHORS>
      <bp:AUTHORS >Aghebati-Maleki A</bp:AUTHORS>
      <bp:AUTHORS >Shanehbandi D</bp:AUTHORS>
      <bp:AUTHORS >Fotouhi A</bp:AUTHORS>
      <bp:AUTHORS >Aghebati-Maleki L</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="bda">
      <bp:ID >22437870</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >The blockade of immune checkpoints in cancer immunotherapy.</bp:TITLE>
      <bp:SOURCE >Nat Rev Cancer</bp:SOURCE>
      <bp:YEAR >2012</bp:YEAR>
      <bp:AUTHORS >Pardoll DM</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:openControlledVocabulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#">
      <bp:TERM xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >cancer</bp:TERM>
      <bp:ID xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >DOID:162</bp:ID>
      <bp:Ontology xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >Disease</bp:Ontology>
    </bp:openControlledVocabulary>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="f89">
      <bp:ID >28990585</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >The diverse functions of the PD1 inhibitory pathway.</bp:TITLE>
      <bp:SOURCE >Nat Rev Immunol</bp:SOURCE>
      <bp:YEAR >2018</bp:YEAR>
      <bp:AUTHORS >Sharpe AH</bp:AUTHORS>
      <bp:AUTHORS >Pauken KE</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ca1">
      <bp:ID >28643244</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Durvalumab: First Global Approval.</bp:TITLE>
      <bp:SOURCE >Drugs</bp:SOURCE>
      <bp:YEAR >2017</bp:YEAR>
      <bp:AUTHORS >Syed YY</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:openControlledVocabulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#">
      <bp:TERM xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >adaptive immune response pathway</bp:TERM>
      <bp:ID xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >PW:0000235</bp:ID>
      <bp:Ontology xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >Pathway Ontology</bp:Ontology>
    </bp:openControlledVocabulary>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="abc">
      <bp:ID >30345906</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.</bp:TITLE>
      <bp:SOURCE >N Engl J Med</bp:SOURCE>
      <bp:YEAR >2018</bp:YEAR>
      <bp:AUTHORS >Schmid P</bp:AUTHORS>
      <bp:AUTHORS >Adams S</bp:AUTHORS>
      <bp:AUTHORS >Rugo HS</bp:AUTHORS>
      <bp:AUTHORS >Schneeweiss A</bp:AUTHORS>
      <bp:AUTHORS >Barrios CH</bp:AUTHORS>
      <bp:AUTHORS >Iwata H</bp:AUTHORS>
      <bp:AUTHORS >Di&#233;ras V</bp:AUTHORS>
      <bp:AUTHORS >Hegg R</bp:AUTHORS>
      <bp:AUTHORS >Im SA</bp:AUTHORS>
      <bp:AUTHORS >Shaw Wright G</bp:AUTHORS>
      <bp:AUTHORS >Henschel V</bp:AUTHORS>
      <bp:AUTHORS >Molinero L</bp:AUTHORS>
      <bp:AUTHORS >Chui SY</bp:AUTHORS>
      <bp:AUTHORS >Funke R</bp:AUTHORS>
      <bp:AUTHORS >Husain A</bp:AUTHORS>
      <bp:AUTHORS >Winer EP</bp:AUTHORS>
      <bp:AUTHORS >Loi S</bp:AUTHORS>
      <bp:AUTHORS >Emens LA</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:openControlledVocabulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#">
      <bp:TERM xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >T cell</bp:TERM>
      <bp:ID xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >CL:0000084</bp:ID>
      <bp:Ontology xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" >Cell Type</bp:Ontology>
    </bp:openControlledVocabulary>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e61">
      <bp:ID >29347993</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after &#8805;1&#160;year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.</bp:TITLE>
      <bp:SOURCE >J Immunother Cancer</bp:SOURCE>
      <bp:YEAR >2018</bp:YEAR>
      <bp:AUTHORS >Kaufman HL</bp:AUTHORS>
      <bp:AUTHORS >Russell JS</bp:AUTHORS>
      <bp:AUTHORS >Hamid O</bp:AUTHORS>
      <bp:AUTHORS >Bhatia S</bp:AUTHORS>
      <bp:AUTHORS >Terheyden P</bp:AUTHORS>
      <bp:AUTHORS >D'Angelo SP</bp:AUTHORS>
      <bp:AUTHORS >Shih KC</bp:AUTHORS>
      <bp:AUTHORS >Lebb&#233; C</bp:AUTHORS>
      <bp:AUTHORS >Milella M</bp:AUTHORS>
      <bp:AUTHORS >Brownell I</bp:AUTHORS>
      <bp:AUTHORS >Lewis KD</bp:AUTHORS>
      <bp:AUTHORS >Lorch JH</bp:AUTHORS>
      <bp:AUTHORS >von Heydebreck A</bp:AUTHORS>
      <bp:AUTHORS >Hennessy M</bp:AUTHORS>
      <bp:AUTHORS >Nghiem P</bp:AUTHORS>
    </bp:PublicationXref>
  <bp:openControlledVocabulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#"><bp:TERM>cancer pathway</bp:TERM><bp:ID>PW:0000605</bp:ID><bp:Ontology>Pathway Ontology</bp:Ontology></bp:openControlledVocabulary></Biopax>
</Pathway>